GlassScriptPhysician profile
David J Chun
NPI 1730152976
$4,564.60
in general payments reported to CMS, 2019-2025
35 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $179 · 2021: $110 · 2022: $609 · 2023: $1,337 · 2024: $993 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.81 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $725.74 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $697.99 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Astrazeneca Pharmaceuticals LP | $288.13 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $287.67 | 2019-2024 | |
| Lilly USA, LLC | $272.78 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $268.24 | 2019-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $265.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $246.25 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $245.57 | 2019-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $234.85 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $171.65 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $106.52 | 2019-2022 | |
| Radius Health, INC. | $78.94 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.10 | 2023-2024 | Xifaxan, Trulance |
| Bausch Health US, LLC | $63.75 | 2022-2025 | Wellbutrin, Aplenzin |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $55.09 | 2023-2025 | Edarbi, Horizant |
| Allergan, INC. | $47.73 | 2019-2020 | |
| Sanofi Pasteur INC. | $47.07 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $41.88 | 2025 | Gemtesa |
| Shield Therapeutics INC | $38.43 | 2022-2023 | Accrufer |
| Axsome Therapeutics, INC. | $33.01 | 2025 | Symbravo |
| Arbor Pharmaceuticals, INC. | $26.34 | 2019 | |
| Boston Scientific Corporation | $25.24 | 2024 | |
| Edwards Lifesciences Corporation | $23.46 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eisai INC. | $22.84 | 2021 | |
| Ibsa Pharma INC. | $22.26 | 2019 | |
| Medtronic USA, INC. | $22.03 | 2019 | |
| Antares Pharma, INC. | $21.06 | 2024 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $20.11 | 2019 | |
| Tolmar, INC. | $17.15 | 2025 | Jatenzo |
| Endogastric Solutions, INC | $16.92 | 2024 | Esophyx |
| Kowa Pharmaceuticals America, INC. | $16.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.63 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.45 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.